Last reviewed 2026-05-20 · How we verify

Centron (ORMELOXIFENE)

Phase 2 active Small molecule ✓ Verified May 2026

Centron (generic name: ORMELOXIFENE) is a ormeloxifene drug. It is currently in Phase 2 development.

Centron works by binding to estrogen receptors in the body, which can help to reduce the growth of certain cells.

Centron is a small molecule. It is also known by the synonyms Centchroman, Centchroman, Centron, Ormeloxifene, Ormeloxifene, and Ormeloxifeno.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ORMELOXIFENE
Drug class	ormeloxifene
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body has locks on the cells that grow and multiply. Centron is a key that fits into these locks, but instead of unlocking the cells, it blocks them from being opened by estrogen. This can help to slow down the growth of certain cells that might be causing problems.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Centron CI brief — competitive landscape report
Centron updates RSS · CI watch RSS

Frequently asked questions about Centron

What is Centron?

Centron (ORMELOXIFENE) is a ormeloxifene drug.

How does Centron work?

Centron works by binding to estrogen receptors in the body, which can help to reduce the growth of certain cells.

What is the generic name of Centron?

ORMELOXIFENE is the generic (nonproprietary) name of Centron.

What drug class is Centron in?

Centron belongs to the ormeloxifene class. See all ormeloxifene drugs at /class/ormeloxifene.

What development phase is Centron in?

Centron is in Phase 2.

Drug class: All ormeloxifene drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing